Ailawadhi Sikander, Bhatia Kirtipal, Aulakh Sonikpreet, Meghji Zahara, Chanan-Khan Asher
Division of Hematology-Oncology, Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL, 32224, USA.
Curr Hematol Malig Rep. 2017 Aug;12(4):309-316. doi: 10.1007/s11899-017-0393-y.
Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics. Research in multiple myeloma has specifically looked at several such patient subgroups based on socioeconomic status, age, race/ethnicity, insurance carrier, and geographic location that may affect healthcare utilization and patient outcomes. Exploring and understanding these would certainly help address disparities and lead to further equity in healthcare access and, hopefully, patient outcomes.
近年来,多发性骨髓瘤的治疗发生了巨大变化,患者的总体治疗效果得到了改善。随着治疗技术的进步,患者护理变得越来越复杂,在基于社会人口统计学因素分析不同患者亚组时,医疗服务的提供以及治疗结果都存在差异。了解这种差异至关重要,这样在总体治疗效果改善的同时,能够特别关注那些可能仍然处于不利地位、无法充分受益于治疗进展的亚组。多发性骨髓瘤的研究专门针对了几个这样的患者亚组,这些亚组基于社会经济地位、年龄、种族/民族、保险公司和地理位置,这些因素可能影响医疗服务的利用和患者的治疗结果。探索和理解这些因素肯定有助于解决差异问题,促进医疗服务获取的进一步公平,并有望改善患者的治疗结果。